A Phase 1 interventional study of AC220 in Acute Myeloid Leukemia, Leukemia and Myelodysplastic Syndrome, sponsored by Daiichi Sankyo. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-11.
Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 12th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 1, and was the 1st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
Kura Oncology, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2007, is one of 12 in phase 1, and was the 2nd registered.
Daiichi Sankyo’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 21 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
This is a multi-center clinical study conducted in the USA and two international sites. This open-label, dose escalation study was designed to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered AC220 as a single agent given daily for 14 days. Cohorts of 3 patients received AC220 until dose limiting toxicity was noted (DLT). At that point cohorts expanded to 6 patients until MTD was determined. Patients not experiencing DLT or significant disease progression at Day 15 may have continued receiving AC220 at the discretion of the Investigator and Sponsor. FLT3 positive and negative patients were allowed to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Histopathologically documented primary or secondary AML, as defined by WHO criteria (Jaffe et al, 2001), confirmed by pathology review at treating institution, meeting at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
Drug: AC220
Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
Also known as: Quizartinib
Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Time frame: Baseline up to 30 days post last dose
Number of Participants With Treatment-emergent Treatment-related Grade 3 or 4 Adverse Events By At Least 10% of All Participants By Dose Group Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Time frame: Baseline up to 30 days post last dose
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.
Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Complete Response (CR) response criteria included either a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying BM assessment. CRp response included all CR criteria met, except participant did not experience a platelet recovery (ANC recovery required). CRi response included a qualifying BM result, but not an ANC recovery. Participants may or may not have had a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline BM assessment carried out, but results did not meet any response criteria. Participants who were not evaluable (NE) did not have at least 14 days of treatment and were not assessed.
Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years
Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Best Overall Response Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Complete Response (CR) response criteria included either a post-baseline bone marrow biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying bone marrow assessment. CRp response included all CR criteria met except participant did not experience a platelet recovery. Participants must have experienced an ANC Recovery. CRi response included a qualifying bone marrow result, but did not experience an ANC recovery. Participants may or may not have experienced a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the bone marrow aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline bone marrow assessment carried out, but results did not meet any of the CR or PR or progressive disease criteria.
Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years
Number of Participants With Hematologic Improvement Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Hematologic improvement is summarized in terms of Erythroid Response (HI-E), Platelet Response (HI-P), Neutrophil Response (HI-N), and Hematologic Improvement (HI). For post-treatment results, HI-E major responders had \>2 g/dL increase in hemoglobin for at least 1 result after first treatment and transfusion independent; minor responders 1 to 2 g/dL increase in hemoglobin for at least 1 result post first treatment and a 50% decrease in red blood cell transfusion requirements. For HI-P, major responders had ≥30 × 10\^9/L increase in platelet count and transfusion independent; minor responders had 50% or more increase in platelet count with a net increase between 10 to 30 × 10\^9/L and 50% decrease in platelet transfusion requirements. For HI-N, major responders had an increase in absolute neutrophil count (ANC) of 100% or an absolute increase of more than 0.5 × 10\^9/L (whichever is greater); minor responders had an increase in ANC of 100% but an absolute increase of \<0.5 × 10\^9/L.
Time frame: Baseline up to 28 days after the last dose, up to approximately 3 years
A total of 76 participants who met all inclusion and no exclusion criteria were enrolled and treated in the study at 4 clinical sites in the United States and 2 sites in the Republic of Georgia.
| Milestone | Quizartinib |
|---|---|
| Started | 76 |
| Completed | 0 |
| Not completed | 76 |
| Withdrew: Adverse event | 6 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Physician decision | 5 |
| Withdrew: Disease progression | 43 |
| Withdrew: Death | 12 |
| Withdrew: Other | 1 |
| Participants | Quizartinib |
|---|---|
| At Least 1 Treatment-Related Adverse Event | 39 |
| General disorders & administration site conditions | 11 |
| Pyrexia | 2 |
| Fatigue | 4 |
| Oedema peripheral | 6 |
| Asthenia | 1 |
| Chills | 1 |
| Malaise | 1 |
| Gastrointestinal disorders | 21 |
| Nausea | 12 |
| Diarrhoea | 6 |
| Vomiting | 8 |
| Abdominal pain | 3 |
| Abdominal pain upper | 2 |
| Dyspepsia | 3 |
| Constipation | 1 |
| Abdominal distension | 2 |
| Gastrointestinal haemorrhage | 1 |
| Gastrooesophageal reflux disease | 1 |
| Abdominal discomfort | 1 |
| Oral mucosal blistering | 1 |
| Epigastric discomfort | 1 |
| Retching | 1 |
| Respiratory, Thoracic, and Mediastinal Disorders | 2 |
| Haemoptysis | 1 |
| Dyspnoea exertional | 1 |
| Blood and Lymphatic System Disorders | 4 |
| Anaemia | 3 |
| Thrombocytopenia | 1 |
| Pancytopenia | 1 |
| Skin and Subcutaneous Tissue Disorders | 8 |
| Periorbital odema | 1 |
| Swelling face | 1 |
| Alopecia | 2 |
| Dry skin | 1 |
| Increased tendency to bruise | 1 |
| Hair colour changes | 1 |
| Hidradenitis | 1 |
| Photosensitivity reaction | 1 |
| Infections and Infestations | 1 |
| Pneumonia | 1 |
| Lung infection | 1 |
| Metabolism and Nutrition Disorders | 7 |
| Hypokalaemia | 2 |
| Anorexia | 5 |
| Hyperglycaemia | 1 |
| Hypoalbuminaemia | 1 |
| Nervous System Disorders | 12 |
| Headache | 2 |
| Dizziness | 1 |
| Dysgeusia | 8 |
| Hypoaesthesia | 1 |
| Neuropathy peripheral | 1 |
| Dysarthria | 1 |
| Investigations | 11 |
| Electrocardiogram QT prolonged | 9 |
| Blood bilirubin increased | 1 |
| Hepatic enzyme increased | 1 |
| Psychiatric Disorders | 1 |
| Insomnia | 1 |
| Cardiac Disorders | 1 |
| Right ventricular dysfunction | 1 |
| Injury, Poisoning, and Procedural Complications | 1 |
| Contusion | 1 |
| Eye Disorders | 1 |
| Eyelid oedema | 1 |
| Hepatobiliary Disorders | 3 |
| Hyperbilirubinaemia | 3 |
| Jaundice | 1 |
| Participants | Quizartinib 12-135 mg ID | Quizartinib 200-450 mg ID | Quizartinib 200-300 mg CD | Total |
|---|---|---|---|---|
| Nausea : All Grades | 6 | 3 | 3 | 12 |
| Nausea : Grade 3-4 | 0 | 0 | 0 | 0 |
| Electrocardiogram QT prolonged : All Grades | 1 | 0 | 8 | 9 |
| Electrocardiogram QT prolonged : Grade 3-4 | 0 | 0 | 4 | 4 |
| Dysgeusia : All Grades | 4 | 1 | 3 | 8 |
| Dysgeusia : Grade 3-4 | 0 | 0 | 0 | 0 |
| Vomiting : All Grades | 3 | 3 | 2 | 8 |
| Vomiting : Grade 3-4 | 1 | 0 | 0 | 1 |
| Anorexia : All Grades | 3 | 1 | 1 | 5 |
| Anorexia : Grade 3-4 | 1 | 0 | 0 | 1 |
| Fatigue : All Grades | 2 | 1 | 1 | 4 |
| Fatigue : Grade 3-4 | 1 | 0 | 1 | 2 |
| Anaemia : All Grades | 2 | 1 | 0 | 3 |
| Anaemia : Grade 3-4 | 2 | 1 | 0 | 3 |
| Hypokalaemia : All Grades | 2 | 0 | 0 | 2 |
| Hypokalaemia : Grade 3-4 | 1 | 0 | 0 | 1 |
| Pyrexia : All Grades | 2 | 0 | 0 | 2 |
| Pyrexia : Grade 3-4 | 1 | 0 | 0 | 1 |
| Eyelid oedema : All Grades | 0 | 1 | 0 | 1 |
| Eyelid oedema : Grade 3-4 | 0 | 1 | 0 | 1 |
| Hypoalbuminaemia : All Grades | 0 | 1 | 0 | 1 |
| Hypoalbuminaemia : Grade 3-4 | 0 | 1 | 0 | 1 |
| Lung infection : All Grades | 0 | 1 | 0 | 1 |
| Lung infection : Grade 3-4 | 0 | 1 | 0 | 1 |
| Pancytopenia : All Grades | 1 | 0 | 0 | 1 |
| Pancytopenia : Grade 3-4 | 1 | 0 | 0 | 1 |
| Photosensitivity reaction : All Grades | 0 | 0 | 1 | 1 |
| Photosensitivity reaction : Grade 3-4 | 0 | 0 | 1 | 1 |
| Thrombocytopenia : All Grades | 0 | 0 | 1 | 1 |
| Thrombocytopenia : Grade 3-4 | 0 | 0 | 1 | 1 |
Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.
| Participants | Quizartinib 12 mg ID | Quizartinib 18 mg ID | Quizartinib 27 mg ID | Quizartinib 40 mg ID | Quizartinib 60 mg ID | Quizartinib 90 mg ID | Quizartinib 135 mg ID | Quizartinib 200 mg ID | Quizartinib 300 mg ID | Quizartinib 450 mg ID | Quizartinib 200 mg CD | Quizartinib 300 mg CD | All Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia | 2 | 2 | 3 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 26 |
Complete Response (CR) response criteria included either a post-baseline bone marrow (BM) biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying BM assessment. CRp response included all CR criteria met, except participant did not experience a platelet recovery (ANC recovery required). CRi response included a qualifying BM result, but not an ANC recovery. Participants may or may not have had a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline BM assessment carried out, but results did not meet any response criteria. Participants who were not evaluable (NE) did not have at least 14 days of treatment and were not assessed.
| Participants | Quizartinib 12 mg ID | Quizartinib 18 mg ID | Quizartinib 27 mg ID | Quizartinib 40 mg ID | Quizartinib 60 mg ID | Quizartinib 90 mg ID | Quizartinib 135 mg ID | Quizartinib 200 mg ID | Quizartinib 300 mg ID | Quizartinib 450 mg ID | Quizartinib 200 mg CD | Quizartinib 300 mg CD | All Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall response | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 6 | 2 | 23 |
| composite CR (CR+CRp+CRi) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 5 | 1 | 10 |
| Complete response (CR) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| CR with incomplete platelet recovery | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| CR with incomplete hematologic recovery | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 5 |
| Partial remission (PR) | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 13 |
| Nonresponder (NR) | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 3 | 0 | 2 | 5 | 2 | 19 |
| Not evaluable (NE) | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 8 |
Progressive disease response criteria included doubling of blast count % in bone marrow (biopsy or aspirate) from baseline; considering measurements starting on Study Day 15, doubling of blast count % in blood from baseline; death determined to be related to disease or disease progression; and investigator reported disease progression.
| Participants | Quizartinib 12 mg ID | Quizartinib 18 mg ID | Quizartinib 27 mg ID | Quizartinib 40 mg ID | Quizartinib 60 mg ID | Quizartinib 90 mg ID | Quizartinib 135 mg ID | Quizartinib 200 mg ID | Quizartinib 300 mg ID | Quizartinib 450 mg ID | Quizartinib 200 mg CD | Quizartinib 300 mg CD | All Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving a Best Disease Response by Dose Cohort in Terms of Progressive Disease Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 1 | 1 | 3 | 18 |
Complete Response (CR) response criteria included either a post-baseline bone marrow biopsy or aspiration % blasts \<5%, absolute neutrophil count (ANC) \>1×10\^9/L and platelet count \>100×10\^9/L on the same date as the qualifying bone marrow assessment. CRp response included all CR criteria met except participant did not experience a platelet recovery. Participants must have experienced an ANC Recovery. CRi response included a qualifying bone marrow result, but did not experience an ANC recovery. Participants may or may not have experienced a platelet recovery and were not required to be transfusion independent. Partial remission (PR) response included a decrease of ≥50% in % blasts in the bone marrow aspirate or biopsy from baseline to a post-baseline result between 5% to 25% in the bone marrow aspirate or biopsy. Nonresponders (NR) had a pre- and 1 or more post-baseline bone marrow assessment carried out, but results did not meet any of the CR or PR or progressive disease criteria.
| Participants | Quizartinib 12 mg ID | Quizartinib 18 mg ID | Quizartinib 27 mg ID | Quizartinib 40 mg ID | Quizartinib 60 mg ID | Quizartinib 90 mg ID | Quizartinib 135 mg ID | Quizartinib 200 mg ID | Quizartinib 300 mg ID | Quizartinib 450 mg ID | Quizartinib 200 mg CD | Quizartinib 300 mg CD | All Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall response | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 6 | 2 | 22 |
| Composite CR (CR+CRp+CRi) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 5 | 1 | 10 |
| Complete response (CR) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| CR with incomplete platelet recovery | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| CR with incomplete hematologic recovery | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 5 |
| Partial remission | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 12 |
| Nonresponder | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 3 | 0 | 2 | 5 | 2 | 19 |
Hematologic improvement is summarized in terms of Erythroid Response (HI-E), Platelet Response (HI-P), Neutrophil Response (HI-N), and Hematologic Improvement (HI). For post-treatment results, HI-E major responders had \>2 g/dL increase in hemoglobin for at least 1 result after first treatment and transfusion independent; minor responders 1 to 2 g/dL increase in hemoglobin for at least 1 result post first treatment and a 50% decrease in red blood cell transfusion requirements. For HI-P, major responders had ≥30 × 10\^9/L increase in platelet count and transfusion independent; minor responders had 50% or more increase in platelet count with a net increase between 10 to 30 × 10\^9/L and 50% decrease in platelet transfusion requirements. For HI-N, major responders had an increase in absolute neutrophil count (ANC) of 100% or an absolute increase of more than 0.5 × 10\^9/L (whichever is greater); minor responders had an increase in ANC of 100% but an absolute increase of \<0.5 × 10\^9/L.
| Participants | Quizartinib |
|---|---|
| Erythroid Response (HI-E) Responders | 35 |
| Erythroid Response (HI-E) Major Responders | 15 |
| Erythroid Response (HI-E) Minor Responders | 20 |
| Erythroid Response (HI-E) No Response | 34 |
| HI-E Participants excluded | 7 |
| Platelet Response (HI-P) Responders | 39 |
| Platelet Response (HI-P) Major Responders | 18 |
| Platelet Response (HI-P) Minor Responders | 21 |
| Platelet Response (HI-P) No Response | 29 |
| HI-P Participants excluded | 8 |
| Neutrophil Response (HI-N) Responders | 26 |
| Neutrophil Response (HI-N) Major Responders | 19 |
| Neutrophil Response (HI-N) Minor Responders | 7 |
| Neutrophil Response (HI-N) No Response | 24 |
| HI-N Participants excluded | 26 |
| Hematologic Improvement (HI) Responders | 60 |
| Hematologic Improvement (HI) Any Major Response | 38 |
| Hematologic Improvement (HI) Any Minor Response | 22 |
| HI Participants excluded | 1 |
Collected over Adverse events were collected from after initiation of study drug up to 30 days after last dose, up to approximately 3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quizartinib 12 mg ID | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Quizartinib 18 mg ID | 8/8 (100%) | 4/8 (50%) | 8/8 (100%) |
| Quizartinib 27 mg ID | 6/6 (100%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Quizartinib 40 mg ID | 5/5 (100%) | 3/5 (60%) | 5/5 (100%) |
| Quizartinib 60 mg ID | 5/5 (100%) | 4/5 (80%) | 5/5 (100%) |
| Quizartinib 90 mg ID | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Quizartinib 135 mg ID | 5/5 (100%) | 4/5 (80%) | 5/5 (100%) |
| Quizartinib 200 mg ID | 5/6 (83.3%) | 3/6 (50%) | 6/6 (100%) |
| Quizartinib 300 mg ID | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Quizartinib 450 mg ID | 6/6 (100%) | 5/6 (83.3%) | 6/6 (100%) |
| Quizartinib 200 mg CD | 16/17 (94.1%) | 9/17 (52.9%) | 15/17 (88.2%) |
| Quizartinib 300 mg CD | 8/8 (100%) | 8/8 (100%) | 8/8 (100%) |
| Event | Quizartinib 12 mg ID | Quizartinib 18 mg ID | Quizartinib 27 mg ID | Quizartinib 40 mg ID | Quizartinib 60 mg ID | Quizartinib 90 mg ID | Quizartinib 135 mg ID | Quizartinib 200 mg ID | Quizartinib 300 mg ID | Quizartinib 450 mg ID | Quizartinib 200 mg CD | Quizartinib 300 mg CD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 0/3 | 2/8 | 0/6 | 1/5 | 4/5 | 1/3 | 1/5 | 2/6 | 1/4 | 4/6 | 5/17 | 3/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/8 | 0/6 | 2/5 | 0/5 | 1/3 | 2/5 | 1/6 | 0/4 | 0/6 | 0/17 | 1/8 |
| PyrexiaGeneral disorders | 0/3 | 0/8 | 0/6 | 0/5 | 0/5 | 1/3 | 0/5 | 0/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| Neutropenic sepsisInfections and infestations | 0/3 | 0/8 | 0/6 | 0/5 | 0/5 | 1/3 | 0/5 | 1/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| Gastrointestinal fungal infectionInfections and infestations | 1/3 | 0/8 | 0/6 | 0/5 | 0/5 | 0/3 | 0/5 | 0/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/8 | 0/6 | 0/5 | 0/5 | 0/3 | 0/5 | 1/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| MelaenaGastrointestinal disorders | 0/3 | 0/8 | 0/6 | 0/5 | 0/5 | 1/3 | 0/5 | 0/6 | 0/4 | 0/6 | 0/17 | 1/8 |
| VomitingGastrointestinal disorders | 1/3 | 0/8 | 0/6 | 0/5 | 0/5 | 0/3 | 1/5 | 0/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| NauseaGastrointestinal disorders | 1/3 | 0/8 | 0/6 | 0/5 | 0/5 | 0/3 | 0/5 | 0/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/8 | 0/6 | 0/5 | 0/5 | 0/3 | 1/5 | 0/6 | 0/4 | 0/6 | 0/17 | 0/8 |
| Event | Quizartinib 12 mg ID | Quizartinib 18 mg ID | Quizartinib 27 mg ID | Quizartinib 40 mg ID | Quizartinib 60 mg ID | Quizartinib 90 mg ID | Quizartinib 135 mg ID | Quizartinib 200 mg ID | Quizartinib 300 mg ID | Quizartinib 450 mg ID | Quizartinib 200 mg CD | Quizartinib 300 mg CD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 1/8 | 1/6 | 2/5 | 1/5 | 3/3 | 3/5 | 2/6 | 0/4 | 1/6 | 1/17 | 3/8 |
| NauseaGastrointestinal disorders | 1/3 | 2/8 | 3/6 | 1/5 | 3/5 | 2/3 | 2/5 | 5/6 | 1/4 | 4/6 | 6/17 | 2/8 |
| Disease progressionGeneral disorders | 0/3 | 2/8 | 0/6 | 1/5 | 4/5 | 1/3 | 1/5 | 2/6 | 1/4 | 4/6 | 5/17 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 3/8 | 1/6 | 0/5 | 2/5 | 1/3 | 1/5 | 3/6 | 1/4 | 4/6 | 4/17 | 3/8 |
| Odema peripheralGeneral disorders | 1/3 | 1/8 | 2/6 | 1/5 | 2/5 | 2/3 | 2/5 | 3/6 | 2/4 | 1/6 | 3/17 | 2/8 |
| VomitingGastrointestinal disorders | 1/3 | 1/8 | 1/6 | 1/5 | 0/5 | 2/3 | 2/5 | 2/6 | 0/4 | 3/6 | 7/17 | 2/8 |
| PetechiaeSkin and subcutaneous tissue disorders | 1/3 | 1/8 | 2/6 | 1/5 | 0/5 | 1/3 | 0/5 | 2/6 | 1/4 | 4/6 | 3/17 | 1/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/3 | 2/8 | 0/6 | 2/5 | 0/5 | 1/3 | 1/5 | 2/6 | 0/4 | 0/6 | 1/17 | 3/8 |
| HeadacheNervous system disorders | 0/3 | 0/8 | 2/6 | 0/5 | 2/5 | 2/3 | 1/5 | 2/6 | 0/4 | 0/6 | 4/17 | 1/8 |
| Abdominal painGastrointestinal disorders | 2/3 | 0/8 | 0/6 | 0/5 | 0/5 | 1/3 | 1/5 | 1/6 | 1/4 | 2/6 | 3/17 | 0/8 |
| Age, Continuous(years) | Quizartinib |
|---|---|
| Mean | 56.0 ± 17.1 |
| Age, Customized(Participants) | Quizartinib |
|---|---|
| <18 years | 0 |
| 18 to 60 years | 39 |
| 61 to 75 years | 31 |
| >75 years | 6 |
| Sex: Female, Male(Participants) | Quizartinib |
|---|---|
| Female | 30 |
| Male | 46 |
| Race (NIH/OMB)(Participants) | Quizartinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 68 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
The record gives a start of Jan 2007, a primary completion of Mar 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2020, 11 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quizartinib